Taoran Li1,2, Julie L Cunningham3, Wesley P Gilliam4, Larissa Loukianova4, Diane M Donegan1,5, Irina Bancos1. 1. Division of Endocrinology, Diabetes and Nutrition, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota. 2. Department of Medicine, Mount Sinai St. Luke's-Roosevelt Hospital, New York, New York. 3. Department of Pharmacy; Mayo Clinic, Rochester, Minnesota. 4. Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota. 5. Division of Endocrinology, Diabetes and Metabolism, Indiana University, Indianapolis, Indiana.
Abstract
CONTEXT: Chronic opioid use may lead to adrenal insufficiency because of central suppression of the hypothalamic-pituitary-adrenal axis. However, the prevalence of opioid-induced adrenal insufficiency (OIAI) is unclear. OBJECTIVE: To determine the prevalence of OIAI and to identify predictors for the development of OIAI in patients taking opioids for chronic pain. DESIGN: Cross-sectional study, 2016-2018. SETTING: Referral center. PATIENTS: Adult patients taking chronic opioids admitted to the Pain Rehabilitation Center. MAIN OUTCOME MEASURE: Diagnosis of OIAI was considered if positive case detection (cortisol < 10 mcg/dL, ACTH < 15 pg/mL, and dehydroepiandrosterone sulfate < 25 mcg/dL), and confirmed after endocrine evaluation. Daily morphine milligram equivalent (MME) was calculated. RESULTS: In 102 patients (median age, 53 years [range, 22-83], 67% women), median daily MME was 60 mg (3-840), and median opioid therapy duration was 60 months (3-360). Abnormal case detection testing was found in 11 (10.8%) patients, and diagnosis of OIAI was made in 9 (9%). Patients with OIAI were on a higher daily MME (median, 140 [20-392] mg vs 57 [3-840] mg, P = 0.1), and demonstrated a 4 times higher cumulative opioid exposure (median of 13,440 vs 3120 mg*months, P = 0.03). No patient taking <MME of 20 mg/day developed OIAI (sensitivity of 100% for MME > 20 mg); however, specificity of MME cutoff >20 mg was only 19%. After opioid discontinuation, 6/7 patients recovered adrenal function. CONCLUSION: The prevalence of OIAI was 9%, with MME cumulative exposure being the only predictor for OIAI development. Patients on MME of 20 mg/day and above should be monitored for OIAI. Published by Oxford University Press on behalf of the Endocrine Society 2020.
CONTEXT: Chronic opioid use may lead to adrenal insufficiency because of central suppression of the hypothalamic-pituitary-adrenal axis. However, the prevalence of opioid-induced adrenal insufficiency (OIAI) is unclear. OBJECTIVE: To determine the prevalence of OIAI and to identify predictors for the development of OIAI in patients taking opioids for chronic pain. DESIGN: Cross-sectional study, 2016-2018. SETTING: Referral center. PATIENTS: Adult patients taking chronic opioids admitted to the Pain Rehabilitation Center. MAIN OUTCOME MEASURE: Diagnosis of OIAI was considered if positive case detection (cortisol < 10 mcg/dL, ACTH < 15 pg/mL, and dehydroepiandrosterone sulfate < 25 mcg/dL), and confirmed after endocrine evaluation. Daily morphine milligram equivalent (MME) was calculated. RESULTS: In 102 patients (median age, 53 years [range, 22-83], 67% women), median daily MME was 60 mg (3-840), and median opioid therapy duration was 60 months (3-360). Abnormal case detection testing was found in 11 (10.8%) patients, and diagnosis of OIAI was made in 9 (9%). Patients with OIAI were on a higher daily MME (median, 140 [20-392] mg vs 57 [3-840] mg, P = 0.1), and demonstrated a 4 times higher cumulative opioid exposure (median of 13,440 vs 3120 mg*months, P = 0.03). No patient taking <MME of 20 mg/day developed OIAI (sensitivity of 100% for MME > 20 mg); however, specificity of MME cutoff >20 mg was only 19%. After opioid discontinuation, 6/7 patients recovered adrenal function. CONCLUSION: The prevalence of OIAI was 9%, with MME cumulative exposure being the only predictor for OIAI development. Patients on MME of 20 mg/day and above should be monitored for OIAI. Published by Oxford University Press on behalf of the Endocrine Society 2020.
Authors: João Valverde-Filho; Malebranche Berardo Carneiro da Cunha Neto; Erich Talamoni Fonoff; Eduardo de Souza Meirelles; Manoel Jacobsen Teixeira Journal: Pain Med Date: 2014-12-17 Impact factor: 3.750
Authors: L-A Fraser; D Morrison; P Morley-Forster; T L Paul; S Tokmakejian; R Larry Nicholson; Y Bureau; T C Friedman; S H M Van Uum Journal: Exp Clin Endocrinol Diabetes Date: 2008-06-03 Impact factor: 2.949
Authors: Martin L Verra; Felix Angst; J Bart Staal; Roberto Brioschi; Susanne Lehmann; André Aeschlimann; Rob A de Bie Journal: BMC Musculoskelet Disord Date: 2012-08-24 Impact factor: 2.362
Authors: Sarpreet S Sekhon; Katelynn Crick; Tyler W Myroniuk; Kevin S C Hamming; Mahua Ghosh; Denise Campbell-Scherer; Roseanne O Yeung Journal: J Endocr Soc Date: 2021-12-09
Authors: Hasan Husni; Mohammed S Abusamaan; Roshan Dinparastisaleh; Lori Sokoll; Roberto Salvatori; Amir H Hamrahian Journal: Front Endocrinol (Lausanne) Date: 2022-08-18 Impact factor: 6.055